Medicare Enrolled
Dr. Tony Makhlouf, MD
Hospitalist Physician · Simi Valley, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Makhlouf from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Makhlouf?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Makhlouf
Dr. Tony Makhlouf is a hospitalist physician in Simi Valley, CA, with 16 years of NPI registration. Based on federal Medicare data, Dr. Makhlouf performed 287,043 Medicare services across 1,750 unique beneficiaries.
Between the years covered by Open Payments, Dr. Makhlouf received a total of $13,935 from 43 pharmaceutical and/or device companies across 775 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hospitalist physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Makhlouf is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years in practice
▲ Top 0% volume in CA
$13,935 industry payments
Medicare Practice Summary
Medicare Utilization ↗287,043
Medicare services
Top 0% in CA for hospitalist physician
1,750
Unique beneficiaries
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~17,940 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) An injection of certolizumab pegol administered under the direct supervision of a physician. |
138,401 | $4 | $8 |
| Tocilizumab injection (Actemra) | 69,445 | $5 | $14 |
| Romosozumab injection (Evenity) for osteoporosis | 28,980 | $8 | $15 |
| Denosumab injection (Prolia/Xgeva) | 13,620 | $19 | $30 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
13,550 | $34 | $99 |
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
10,050 | $10 | $38 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
4,339 | $25 | $100 |
| Rituximab injection, 10 mg Administration of a 10 mg dose of rituximab medication via injection. |
4,331 | $62 | $193 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,441 | $102 | $181 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
776 | $66 | $149 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
521 | $122 | $343 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
355 | $1 | $3 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
244 | $26 | $135 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
195 | $14 | $128 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
177 | $135 | $274 |
| Ultrasound-guided large joint aspiration or injection This procedure uses ultrasound imaging to guide the removal of fluid from or the injection of medication into a large joint. |
113 | $87 | $155 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
111 | $74 | $123 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
95 | $1 | $14 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
81 | $98 | $580 |
| Methylprednisolone injection, up to 40 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg. |
74 | $3 | $24 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
40 | $65 | $409 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
32 | $56 | $102 |
| Hospital discharge management, 30+ min This service covers the care provided by a physician or qualified healthcare professional on the day a patient is discharged from the hospital. It requires more than 30 minutes of total time spent on the day of discharge. |
26 | $95 | $616 |
| Joint fluid aspiration or injection, small joint Removal of fluid from a small joint or injection of medication into a small joint. |
16 | $40 | $80 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
16 | $79 | $150 |
| Virtual check-in for established patient A brief communication service provided by a qualified healthcare professional to an established patient via technology, such as a virtual check-in. |
14 | $11 | $46 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
9.9% high complexity
89.4% medium
0.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$13,935
Total received (2018-2024)
Avg $1,991/year across 7 years
Top 2% in CA for hospitalist physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
43
Companies
775
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,835 (99.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$100 (0.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,354
2023
$2,058
2022
$2,156
2021
$606
2020
$1,127
2019
$2,928
2018
$1,707
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$1,227
Amgen Inc.
$679
Janssen Biotech, Inc.
$341
Novartis Pharmaceuticals Corporation
$287
UCB, Inc.
$216
Radius Health, Inc.
$105
GlaxoSmithKline, LLC.
$70
PFIZER INC.
$64
Kiniksa Pharmaceuticals International, plc
$58
AstraZeneca Pharmaceuticals LP
$52
Alexion Pharmaceuticals, Inc.
$46
SOBI, INC
$45
Genentech USA, Inc.
$36
VERTEX PHARMACEUTICALS INCORPORATED
$35
Organon Llc
$30
Boehringer Ingelheim Pharmaceuticals, Inc.
$26
Teleflex LLC
$21
Fresenius Kabi USA, LLC
$15
Top 3 companies account for 67.0% of 2024 payments
All-time payments by company (2018-2024) ›
ABBVIE INC.
$2,563
Amgen Inc.
$2,433
Janssen Biotech, Inc.
$1,477
Novartis Pharmaceuticals Corporation
$1,178
AbbVie, Inc.
$694
PFIZER INC.
$567
Lilly USA, LLC
$546
AbbVie Inc.
$432
GlaxoSmithKline, LLC.
$402
UCB, Inc.
$354
Radius Health, Inc.
$338
GENZYME CORPORATION
$330
Horizon Therapeutics plc
$305
Celgene Corporation
$295
Genentech USA, Inc.
$207
Mallinckrodt Enterprises LLC
$181
AstraZeneca Pharmaceuticals LP
$169
Mallinckrodt LLC
$150
Osiris Therapeutics Inc.
$123
SANOFI-AVENTIS U.S. LLC
$100
Janssen Scientific Affairs, LLC
$90
Amniox Medical, Inc.
$90
SOBI, INC
$75
MEDEXUS PHARMA, INC.
$71
Boehringer Ingelheim Pharmaceuticals, Inc.
$70
Janssen Pharmaceuticals, Inc
$68
E.R. Squibb & Sons, L.L.C.
$66
KCI USA, Inc
$66
Kiniksa Pharmaceuticals International, plc
$58
MEDAC PHARMA, INC.
$54
Teleflex LLC
$53
Alexion Pharmaceuticals, Inc.
$46
Bioventus LLC
$39
VERTEX PHARMACEUTICALS INCORPORATED
$35
Horizon Pharma plc
$32
Flexion Therapeutics, Inc.
$31
Organon Llc
$30
Kiniksa Pharmaceuticals, Ltd.
$24
Sobi, Inc
$22
Abbott Laboratories
$21
Vertiflex, Inc.
$19
Mallinckrodt Hospital Products Inc.
$15
Fresenius Kabi USA, LLC
$15
Top 3 companies account for 46.5% of all-time payments
Associated products mentioned in payments ›
ACTHAR · Actemra · Arcalyst · BENLYSTA · Bimzelx · COSENTYX · Cimzia · DUEXIS · ELIQUIS · EVENITY · Enbrel · FARXIGA · FORTEO · GELSYN 3 · GELSYN-3 · HUMIRA · Humira · INFLECTRA · KEVZARA · KINERET · KRYSTEXXA · Kineret · NEOX · OFEV · OLUMIANT · ORENCIA · Otezla · PENNSAID · Proclaim Family of SCS IPGs · Prolia · RAYOS · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · Stravix · Superion ISS · TALTZ · TAVNEOS · TREMFYA · Tymlos · UROLIFT · XARELTO · XELJANZ · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 2% for hospitalist physician in CA.
Geographic Context
Hospitalist physicians within 10 mi
182
Per 100K population
21.7
County median income
$107,327
Nearest hospital
ADVENTIST HEALTH SIMI VALLEY
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Makhlouf is a mixed practice specialist, with above-average Medicare volume (top 0% in CA), with low-engagement industry engagement in the top 2% of CA peers, with 16 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Makhlouf experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Makhlouf performed 138,401 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Makhlouf receive payments from pharmaceutical companies?
Yes. Dr. Makhlouf received a total of $13,935 from 43 companies across 775 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Makhlouf's costs compare to other hospitalist physicians in Simi Valley?
Dr. Makhlouf's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Makhlouf) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hospitalist Physicians in Simi Valley
Browse hospitalist physicians in Simi Valley ranked by procedure volume and transparency data.
Highest volume
Top Hospitalist Physicians in CA
Hospitalist physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hospitalist Physicians in CA
Which CA hospitalist physicians receive the most from drug and device companies.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology